Skip to main content
. 2019 Jan 11;10(4):494–510. doi: 10.18632/oncotarget.26563

Figure 3. Baseline BCL-xL expression and inhibition of BCL-xL with ABT-263 (navitoclax) treatment of HNSCC cells, alone and in combination with radiation or cisplatin.

Figure 3

(A) Western blot demonstrating consistent high expression of BCL-xL and rare expression of BCL-2 in HNSCC cells. (B) Average IC50 values, with S.E.M. (error bars), after treatment with ABT-263 (navitoclax) assessed from cell viability assays using MTT. (C) Percent Survival calculated from clonogenic survival assays, with S.E.M. (error bars), after treatment of HNSCC cells with 2μM or 4μM ABT-263 (navitoclax) alone or in combination with 2 Gy radiation. (D) Average IC50 values, with S.E.M. (error bars), for cisplatin given in combination with 2μM and 4 μM ABT-263 (navitoclax).